Oxford spin-out @AlethioTx, a #biopharmaceutical company developing next-generation #therapies for myeloproliferative neoplasms (MPNs), has completed an oversub...
Oxford spin-out @AlethioTx, a #biopharmaceutical company developing next-generation #therapies for myeloproliferative neoplasms (MPNs), has completed an oversubscribed €80.46 million Series A financing. 🇬🇧 🧬 🩸
